London-based biotech startup Baseimmune has raised $11.3 million (£9 million) in Series A financing to advance its machine learning platform for streamlined vaccine design. The oversubscribed round welcomed new lead investors MSD Global Health Innovation Fund and IQ Capital, with additional support from early backers Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc.
总部位于伦敦的生物技术初创公司 Baseimmune 在 A 轮融资中筹集了 1130 万美元（900 万英镑），以推进其用于简化疫苗设计的机器学习平台。本轮超额认购迎来了新的主要投资者 MSD Global Health Innovation Fund 和 IQ Capital，早期支持者 Hoxton Ventures、Creator Fund、Beast Ventures 和 Maki.vc 也提供了额外支持。
Founded in 2019, Baseimmune leverages proprietary deep learning algorithms to predict future mutations of pathogens and design synthetic antigen proteins that can provide broader, longer-lasting immune protection. This AI-driven approach aims to create universally effective “future-proof” vaccines that keep pace with pathogen evolution.
Baseimmune 成立于 2019 年，利用专有的深度学习算法来预测病原体的未来突变，并设计可提供更广泛、更持久的免疫保护的合成抗原蛋白。这种人工智能驱动的方法旨在创造普遍有效的“面向未来”的疫苗，与病原体进化保持同步。
“We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital,” said Baseimmune CEO Joshua Blight. “This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens. We are more excited than ever about the possibilities.”
Baseimmune 首席执行官 Joshua Blight 表示：“我们很高兴得到默沙东全球健康创新基金和 IQ Capital 领导的顶级投资者财团的支持。” “这笔资金将使我们能够加速技术开发，扩大项目规模，并加快针对未来病原体的有效疫苗的交付。我们对这些可能性比以往任何时候都更加兴奋。”
The new capital will support advancement of Baseimmune’s vaccine candidates for African swine fever, COVID-19, and malaria, currently progressing through preclinical development. The company also plans to grow its technical team, expand its AI platforms, and initiate further vaccine discovery programs targeting infectious disease.
新资金将支持 Baseimmune 针对非洲猪瘟、COVID-19 和疟疾的候选疫苗的进展，目前该疫苗正在进行临床前开发。该公司还计划扩大其技术团队，扩展其人工智能平台，并启动针对传染病的进一步疫苗发现计划。
At the heart of any vaccine is the pathogen-derived antigen that teaches our immune system how to recognize and neutralize infections. Conventional approaches identify single antigenic proteins such as viral spike proteins. But pathogens mutate rapidly, enabling them to evade immune defenses targeted at static antigens.
任何疫苗的核心都是病原体衍生的抗原，它教会我们的免疫系统如何识别和中和感染。传统方法识别单一抗原蛋白，例如病毒刺突蛋白。但病原体会迅速突变，使它们能够逃避针对静态抗原的免疫防御。
Baseimmune’s computational vaccine design platform crunches evolutionary, genomic, clinical, and immunological data to create multi-component antigen proteins encompassing crucial present and predicted future mutations across entire pathogen genomes. The company’s AI models can generate synthetic antigen blueprints in silico for accelerated vaccine prototyping and testing compared to traditional empirical guesswork.
Baseimmune 的计算疫苗设计平台处理进化、基因组、临床和免疫学数据，以创建多组分抗原蛋白，涵盖整个病原体基因组中当前和预测的关键突变。与传统的经验猜测相比，该公司的人工智能模型可以在计算机中生成合成抗原蓝图，以加速疫苗原型设计和测试。
“We believe Baseimmune’s technology marks a significant advancement in proactive, adaptable vaccine solutions,” said David M. Rubin of lead investor MSD Global Health Innovation Fund. “We are excited to support this forward-looking team.”
“我们相信 Baseimmune 的技术标志着主动、适应性强的疫苗解决方案的重大进步，”主要投资者默沙东全球健康创新基金的 David M. Rubin 表示。 “我们很高兴能够支持这个具有前瞻性的团队。”
These computationally derived antigens can integrate into multiple delivery platforms such as mRNA, viral vectors, or DNA to enhance the efficacy and longevity of resulting vaccine formulations. In this way, Baseimmune provides plug-and-play antigen innovation to complement cutting edge vaccine technologies while mitigating the need for yearly vaccine redesign against mutable threats.
这些计算得出的抗原可以整合到多个递送平台中，例如 mRNA、病毒载体或 DNA，以增强疫苗制剂的功效和寿命。通过这种方式，Baseimmune 提供了即插即用的抗原创新，以补充尖端疫苗技术，同时减少每年针对可变威胁重新设计疫苗的需要。
In an age of growing anti-vaccine sentiments, next-generation vaccine platforms may be crucial for maintaining public health. In particular, preparedness for potential pandemics demands tools that can respond quickly to emerging infectious diseases.
在反疫苗情绪日益高涨的时代，下一代疫苗平台可能对维护公众健康至关重要。特别是，为潜在的流行病做好准备需要能够快速应对新出现的传染病的工具。
“Modelling pathogen evolution and immune response, Baseimmune’s platform pioneers the next generation of universal vaccines against complex pathogens that have been failed by traditional approaches,” said investor Alex Wilson of IQ Capital. “Generating cross-protective, mutation-resistant vaccines, this cutting-edge biotech could transform our ability to combat existential threats from COVID to malaria.”
IQ Capital 的投资者 Alex Wilson 表示：“Baseimmune 的平台通过对病原体进化和免疫反应进行建模，开创了针对传统方法失败的复杂病原体的下一代通用疫苗的先河。” “这种尖端生物技术可以产生交叉保护、抗突变的疫苗，可以改变我们应对从新冠病毒到疟疾等生存威胁的能力。”
Baseimmune’s founding team combines PhD immunologists and vaccinologists from Oxford University with machine learning engineers. With infectious diseases causing over 10 million deaths globally each year, the startup’s fusion of AI and biotech could prove a pivotal innovation in the quest to preempt and control disease outbreaks worldwide.
Baseimmune的创始团队由来自牛津大学的免疫学家和疫苗学家博士以及机器学习工程师组成。由于传染病每年在全球造成超过 1000 万人死亡，这家初创公司将人工智能和生物技术融合起来，可能会成为在全球范围内预防和控制疾病爆发的关键创新。
【来源】https://www.maginative.com/article/baseimmune-closes-11-3m-series-a-to-accelerate-ai-designed-vaccines/
Views: 0